# ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion

Study · id `cardio:ct-nct05225961` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05225961](<https://clinicaltrials.gov/study/NCT05225961>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05225961

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 240 participants.

## Technical summary

Registry record NCT05225961. Randomized; single masking; primary purpose treatment. Start 2026-03-20 (actual); primary completion 2026-03-20 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 240 participants (enrolled count; ClinicalTrials.gov record NCT05225961, source copy `cardio:ctgov-nct05225961-2026-04-03`, retrieved 2026-10-26)
- Started: 2026-03-20 (actual) (ClinicalTrials.gov record NCT05225961, source copy `cardio:ctgov-nct05225961-2026-04-03`, retrieved 2026-10-26)
- Primary completion: 2026-03-20 (actual) (ClinicalTrials.gov record NCT05225961, source copy `cardio:ctgov-nct05225961-2026-04-03`, retrieved 2026-10-26)
- Completion: 2026-03-20 (actual) (ClinicalTrials.gov record NCT05225961, source copy `cardio:ctgov-nct05225961-2026-04-03`, retrieved 2026-10-26)
- Countries: Spain (ClinicalTrials.gov record NCT05225961, source copy `cardio:ctgov-nct05225961-2026-04-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05225961-2026-04-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion
- Acronym: ATILA
- Condition: Acute Ischemic Stroke
- Intervention (Drug): Tirofiban
- Intervention (Drug): Acetylsalicylic acid
- Lead sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)

## Provenance

Content hash: 5b21418d97f6c0395d8e7d8543f9ebb969633d44742045cb0c01112bf7273fe3
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
